English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

DSC3 is a transmembrane cell adhesion protein. In carcinomas, DSC3 is either upregulated with its distribution as membrane and cytoplasmic protein or downregulated with undetectable DSC3 expression. The chemotherapeutic agent viz. gemcitabine, paclitaxel, cisplatin and doxorubicin known to induce the expression of cell adhesion molecules in cancer cells. We report the expression of DSC3 affected by these drugs in cancer cell lines originated from pancreatic cancer, lung cancer, melanoma and kidney fibroblast. At sub-therapeutic doses, all the DSC3 negative cell lines expressed DSC3 before death. In DSC3 positive cell lines, DSC3 conversion was less common. The conversion in DSC3 expression found variable with each drug and cell line evaluated. During drug treatment, we have observed localized expression of DSC3. For DSC3 negative cell lines membrane and cytoplasm are early to become DSC3 positive compared to nucleus; however, for DSC3 positive cell lines, nuclear negative DSC3 first observed in drug treated cells. The conversion of DSC3 in live cells is reversible in native condition. This study emphasize the status of DSC3 during chemotherapeutic drug treatment is crucial for resistance and can be an ideal target for combined therapies.

CANCER: EFFECT OF CHEMOTHERAPEUTIC AGENTS ON DSC3 EXPRESSION